Trial · NCT05448755
Results by group19
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 19 of 19
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants With Adverse Events Associated With Administration of 0.75 mg/kg of ELX-02 Once Daily | Study Treatment: ELX-02 0.75 mg/kg | 3 | Participants | ||
| Change From Baseline in Proteinuria | ELX-02 Patient 1 | Baseline | 1299.5 | Standard Deviation 1.37 | mg/g |
| Change From Baseline in Proteinuria | ELX-02 Patient 2 | Baseline | 1646.3 | Standard Deviation 1.24 | mg/g |
| Change From Baseline in Proteinuria | ELX-02: Patient 3 | Baseline | 1645.3 | Standard Deviation 1.26 | mg/g |
| Change From Baseline in Proteinuria | ELX-02 Patient 1 | Week 4 | 1943.3 | Standard Deviation 1.13 | mg/g |
| Change From Baseline in Proteinuria | ELX-02 Patient 2 | Week 4 | 706.8 | Standard Deviation 1.25 | mg/g |
| Change From Baseline in Proteinuria | ELX-02: Patient 3 | Week 4 | 3522.2 | Standard Deviation 1.14 | mg/g |
| Change From Baseline in Proteinuria | ELX-02 Patient 1 | End of Treatment | 2465.7 | Standard Deviation 1.7 | mg/g |
| Change From Baseline in Proteinuria | ELX-02 Patient 2 | End of Treatment | 1028.1 | Standard Deviation 1.65 | mg/g |
| Change From Baseline in Proteinuria | ELX-02: Patient 3 | End of Treatment | 2634.7 | Standard Deviation 1.2 | mg/g |
| Change From Baseline to End of Treatment in Collagen IV Expression (Combined Average of Alpha 3 and Alpha 4 Chains) | ELX-02 Patient 1 | 38.5 | percentage of change from baseline | ||
| Change From Baseline to End of Treatment in Collagen IV Expression (Combined Average of Alpha 3 and Alpha 4 Chains) | ELX-02 Patient 2 | 8.3 | percentage of change from baseline | ||
| Change From Baseline to End of Treatment in Collagen IV Expression (Combined Average of Alpha 3 and Alpha 4 Chains) | ELX-02: Patient 3 | 170.8 | percentage of change from baseline | ||
| Change From Baseline to End of Treatment in Collagen IV Expression (Foot Process Width in Renal Biopsy) | ELX-02 Patient 1 | -18.7 | percentage of change from baseline | ||
| Change From Baseline to End of Treatment in Collagen IV Expression (Foot Process Width in Renal Biopsy) | ELX-02 Patient 2 | 6.8 | percentage of change from baseline | ||
| Change From Baseline to End of Treatment in Collagen IV Expression (Foot Process Width in Renal Biopsy) | ELX-02: Patient 3 | -45 | percentage of change from baseline | ||
| Change From Baseline to End of Treatment in Collagen IV Expression (Filtration Slit Density in Renal Biopsy) | ELX-02 Patient 1 | 0.496 | Change from baseline in µm-1 | ||
| Change From Baseline to End of Treatment in Collagen IV Expression (Filtration Slit Density in Renal Biopsy) | ELX-02 Patient 2 | 0.207 | Change from baseline in µm-1 | ||
| Change From Baseline to End of Treatment in Collagen IV Expression (Filtration Slit Density in Renal Biopsy) | ELX-02: Patient 3 | 0.931 | Change from baseline in µm-1 |
Source ClinicalTrials.govtrials-2026-11-12-0.4.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT05448755/results